Business Context and Reporting Period
This Form 8-K was filed by Aileron Therapeutics, Inc. (noting a discrepancy with the request metadata which listed "Rein Therapeutics, Inc.") on September 13, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol ALRN. The filing serves as a Regulation FD disclosure regarding the posting of a Corporate Presentation on the company's website.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this specific 8-K filing. The sole reported event is the dissemination of a Corporate Presentation to investors.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in the referenced Corporate Presentation is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the presentation is not subject to the liabilities of that section nor incorporated by reference into other filings, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the correct company name is Aileron Therapeutics, Inc. (ALRN), not Rein Therapeutics, Inc.
- Access the "Investors & Media" section of the company website (www.aileronrx.com) to review the Corporate Presentation referenced in Item 7.01.
- Confirm that the presentation is not legally incorporated by reference into this filing unless explicitly stated elsewhere.
- Note that the company is classified as an emerging growth company.